Summary

Global Viscosupplementation Market Size

Viscosupplementation market is expected to reach US$ 10.16 billion by 2033 from US$ 4.66 billion in 2024, with a CAGR of 9.02% from 2025 to 2033. Among the major reasons propelling the market are the rising incidence of osteoporosis and osteoarthritis (OA) as well as consumers' growing preference for minimally invasive non-surgical therapies.


Viscosupplementation Industry Overview

The medical treatment known as viscosupplementation may be helpful for patients with osteoarthritis of the hip, knee, ankle, or spine. The treatment can also be used to treat other types of joint discomfort. The initial line of treatment is often to administer a numbing shot to the region surrounding the knee joint. By doing this, any excess fluid will be eliminated, avoiding joint swelling. Hyaluronic acid will be injected into the joint's inside after a while. Consequently, part of the lubricating properties of the synovial fluid that normally lubricates the joint are gradually lost. Fluid reduces friction in the system by lubricating the joints and softening them. It has a thick gel-like viscosity. This illusion is caused by the thick gel-like viscosity of the liquid.

Hyaluronic acid levels in the joints of people with osteoarthritis are significantly lower than those of healthy people. Their soreness, edema, and stiffness all contribute to their suffering. The patient may have pain even after receiving an injection of hyaluronic acid into a joint. Patients may feel less discomfort after completing the prescribed course of treatment.

People are pursuing this therapy in order to maintain an active lifestyle and either prevent or postpone the necessity for total knee replacement surgery. The increasing number of obese people and the aging population are the main causes of the rising prevalence of osteoarthritis (OA) worldwide. Although there is no known cure for arthritis, numerous therapeutic alternatives have been developed to help those who suffer from it carry out their everyday activities more easily.
For example, according to data released by the World Health Organization (WHO) in July 2023, there were over 528 million individuals worldwide who suffered from osteoarthritis in 2019. Seventy-three percent of the 528 million individuals are above the age of fifty-five. It is projected that the prevalence of osteoarthritis will continue to rise worldwide due to aging populations and rising injury rates.

In a similar vein, the Osteoarthritis (OA) Action Alliance reported in August 2019 that approximately 32.5 million Americans suffered from osteoarthritis in 2019. As a result, the increasing prevalence of osteoarthritis in patients is anticipated to fuel demand for these therapies, which improve lubrication to alleviate joint discomfort, hence propelling market expansion throughout the course of the forecast year.


Growth Drivers for the Viscosupplementation Market

The aging population's rising prevalence of osteoarthritis raises need for efficient treatments, which propels market expansion

Globally, the prevalence of age-related illnesses, especially osteoarthritis, is rising. In recent years, intra-articular injection of hyaluronic acid derivatives, often known as viscosupplementation, has grown in popularity among therapeutic approaches. For example, the World Health Organization (WHO) reported that there were 1 billion people in 2019 who were 60 years of age or older. By 2030, this figure is predicted to rise to 1.40 billion, and by 2050, it will reach 2.10 billion.
Furthermore, another factor driving the market's expansion is the rising incidence of osteoarthritis. For example, according to data published by the Lancet in August 2023, osteoarthritis affected around 15.0% of those aged 30 and over in 2020. By the end of 2050, it is estimated that 1 billion people would have osteoarthritis worldwide.

Similarly, according to data released by the World Health Organization (WHO) in July 2023, osteoarthritis affected approximately 528.0 million individuals globally in 2019. Of those with osteoarthritis, 60.0% were women and 73.0% were over the age of 55. Throughout the forecast period, the need for hyaluronic acid-based injections for effective treatment is anticipated to be driven by the aging population and the increasing incidence of osteoarthritis.


Hyaluronic acid-based injection sales have been rising due to the growing need for non-surgical treatments for osteoarthritis, which is propelling market expansion

One of the reasons propelling the market's expansion is the rising demand for osteoarthritis non-surgical treatment. Another therapeutic option for osteoarthritis is viscosupplementation, which is used when more conservative approaches are unsuccessful and surgery is not a possibility. Furthermore, patients who require knee surgery to treat osteoarthritis may be able to postpone or delay the procedure by using viscosupplement injections.

For instance, patients who had a single hyaluronic acid injection were able to delay surgery by 1.4 years, according to data released by Peak Health and Wellness in November 2023. On average, patients who had five or more injections were able to put off surgery for 3.6 years. Thus, one reason driving market expansion is the growing use of non-surgical techniques, like hyaluronic acid-based injections, to postpone osteoarthritic procedures.


Minimally Invasive Nature:

Patients find viscosupplementation very intriguing because it is minimally invasive. In order to relieve the pain and inflammation brought on by osteoarthritis and other joint disorders, hyaluronic acid is injected into the joint. Viscosupplementation, in contrast to surgery, is usually done as an outpatient procedure without the requirement for general anesthesia, enabling patients to promptly resume their regular activities. For many people, especially those who are not candidates for surgery, the technique is a safer option because it typically has fewer adverse effects than more intrusive procedures. Additionally, patients looking for efficient joint pain management with little disturbance to their lifestyle may find viscosupplementation to be a compelling alternative because to the comparatively low risk of consequences and the ease of a non-surgical method.


Challenges in the Viscosupplementation Market

The high cost of therapy may limit market expansion

Osteoarthritis patients may require multiple injections of the expensive viscosupplementation treatment. Additionally, some of the physicians said that these injections' efficacy varies. For instance, according to data from the Arthritis Society Canada in December 2021, viscosupplementation injections cost between $200 and $350 each course of treatment.

Furthermore, the increased expense of this therapy prevents middle-class individuals and those residing in developing nations in the Asia-Pacific and Middle East and Africa from affording it, hence restricting its utilization. Therefore, throughout the projection period, the high cost of injections based on hyaluronic acid and the overall treatment of osteoarthritis are anticipated to limit the growth of the viscosupplementation market.


Short-Term Relief

The short-term nature of viscosupplementation's benefits is one of its primary drawbacks. Repeat injections may be required to sustain the pain reduction and increased joint function that patients usually experience for a few months. Given that several treatments can be needed over time, this can cause worries about the long-term expenses. Because viscosupplementation is only temporary, some patients may decide to pursue more permanent options, such joint replacement surgery, particularly if their osteoarthritis worsens. Furthermore, the requirement for continuous injections could raise concerns regarding the general efficacy and cost-effectiveness of viscosupplementation as a long-term therapy. As a result, while thinking about long-term management plans, patients and healthcare professionals may take into account other therapies, including surgery.


Osteoarthritis of the knee became the market leader for viscosupplementation

The knee osteoarthritis segment has asserted its dominance in the viscosupplementation market, primarily fueled by the escalating prevalence of knee osteoarthritis and the increasing geriatric population, which is more prone to this condition. The aging demographic is particularly susceptible to knee osteoarthritis due to the aging process, leading to a reduction in the water content of cartilage. This diminishes its capacity to absorb shock and provide cushioning, making older people more susceptible to knee-related ailments. The significant prevalence of knee osteoarthritis and its correlation with age underscore the prominence of this segment within the viscosupplementation market.


Every year, the market for orthopedic clinics and ambulatory surgical centers grows

The orthopedic clinics and ambulatory surgical centers market is witnessing consistent annual growth. This trend indicates the increasing demand for specialized orthopedic services and the adoption of outpatient surgical procedures. Patients increasingly prefer these facilities for convenience, efficient services, and reduced hospitalization time. Additionally, advancements in medical technology and the emphasis on providing comprehensive orthopedic care contribute to the sustained expansion of this market. As healthcare continues to evolve towards more patient-centric models, the growth of orthopedic clinics and ambulatory surgical centers reflects the changing landscape of orthopedic healthcare services.


Viscosupplementation Market Overview by Regions

By countries, the global Viscosupplementation market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, and South Africa.


United States Viscosupplementation Market

The rising incidence of osteoarthritis, especially in the elderly population, is fueling the continuous expansion of the viscosupplementation industry in the United States. Viscosupplementation is a common option for treating osteoarthritis in the knee since it provides patients with better mobility and joint pain alleviation without requiring surgery. Improvements in hyaluronic acid formulations, which increase therapy efficacy and safety, are driving the market. Demand is also being driven by increased knowledge of osteoarthritis and the advantages of viscosupplementation. However, some patients continue to face obstacles due to the high cost of treatment and difficulties with insurance reimbursement. Despite this, the market is still growing since people are choosing non-surgical choices and there is a growing need for minimally invasive therapies. It is anticipated that ongoing advancements and increased access to healthcare will further propel market expansion.

For example, an article named "Osteoarthritis" from the Centers for Disease Control and Prevention in April 2020 states that approximately 32.5 million Americans suffer from osteoarthritis. In addition, osteoarthritis affects 62% of women.


Germany Viscosupplementation Market

The rising prevalence of osteoarthritis, especially in the elderly population, is fueling the growth of the viscosupplementation market in Germany. Germany, one of the biggest healthcare markets in Europe, has witnessed an increase in the need for non-invasive joint pain management and mobility-enhancing procedures like viscosupplementation. Many patients choose to use viscosupplementation instead of surgery because of the nation's sophisticated healthcare system and high patient awareness levels. Newer hyaluronic acid formulations that give longer-lasting comfort and increased potency are also being used by German healthcare practitioners. But there are also obstacles like exorbitant medical expenses and problems with payment, especially for people with severe osteoarthritis. Nevertheless, the market is expected to rise further because of the growing demand for minimally invasive procedures and improvements in medical technology.


India Viscosupplementation Market

Due in large part to the increasing incidence of osteoarthritis, especially in the elderly population, the viscosupplementation industry in India is growing quickly. Viscosupplementation is becoming more and more well-liked as an affordable, minimally invasive therapeutic option for joint pain management and mobility enhancement, particularly in urban locations. Growing knowledge of joint health and the advantages of viscosupplementation, as well as the expanding selection of sophisticated hyaluronic acid products, are factors driving the market. Widespread adoption is nevertheless hampered by issues such inconsistent healthcare availability in remote areas, high treatment costs, and restricted insurance coverage. The market is expected to expand in spite of these obstacles, as improved medical infrastructure, more access to healthcare, and increased disposable incomes all support the use of viscosupplementation treatments. It is anticipated that the need for non-surgical substitutes would support market growth even more.

64.3% of the elderly population has knee osteoarthritis, and those who have it have a significantly lower quality of life, according to a January 2021 article titled "Prevalence of knee osteoarthritis, its determinants, and impact on the quality of life in elderly persons in rural Ballabgarh, Haryana" published by the National Center for Biotechnology Information. Moreover, another risk factor for orthopedic disorders is obesity. For example, 'Prevalence of Obesity in India and its Neurological Implications: A Multifactor Analysis of a Nationwide Cross-Sectional Study,' published in 2021 by the National Center for Biotechnology Information, states that 40.3% of Indians are obese. Furthermore, South India has the highest prevalence rate (46.51%), while East India has the lowest (32.96%).


Saudi Arabia Viscosupplementation Market

The rising incidence of osteoarthritis, particularly in the elderly and active populations, is fueling the Saudi Arabian viscosupplementation market's continuous expansion. Viscosupplementation is gaining popularity as a non-invasive remedy for joint discomfort and mobility problems in place of surgery. Saudi Arabia's sophisticated healthcare system and expanding awareness of joint health, as seen by the growing number of healthcare providers providing viscosupplementation therapies, are factors driving the market. Furthermore, the government's emphasis on enhancing healthcare quality and accessibility under Vision 2030 is probably going to encourage additional expansion. But issues like exorbitant medical bills and inadequate insurance coverage still exist. Notwithstanding these challenges, the need for affordable, minimally invasive procedures is anticipated to fuel the growth of the nation's viscosupplementation market.


Product – Market have been covered from 3 viewpoints
1. Single Injection Viscosupplementation
2. Three Injections Viscosupplementation
3. Five Injections Viscosupplementation


Application – Market have been covered from 5 viewpoints
1. Knee
2. Hip
3. Hand/Wrist
4. Ankle/Foot
5. Others


End User – Market have been covered from 2 viewpoints
1. Hospitals
2. Orthopedic clinics/Ambulatory Surgical Centers


Region – Market have been covered from 25 Countries viewpoints
1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa


Company Analysis
• Overview
• Recent Development
• Revenue


Companies Covered
1. Anika Therapeutics Inc
2. Zimmer Biomet
3. Smith & Nephew PLC
4. F.Hoffmann-La Roche Ltd
5. Sanofi
6. Chugai Pharmaceutical Co
7. Lifecore Biomedical
8. LG Life Sciences Ltd


Key Questions Answered in Report:
1. How big is the Viscosupplementation industry?
The global Viscosupplementation market size was valued at US$ 4.66 billion in 2024 and is expected to reach US$ 10.16 billion in 2033.

2. What is the Viscosupplementation growth rate?
The global Viscosupplementation market is expected to expand at a compound annual growth rate (CAGR) of 9.02% from 2025 to 2033.

3. Who are the key players in Viscosupplementation industry?
Some key players operating in the Viscosupplementation market includes Anika Therapeutics Inc, Zimmer Biomet, Smith & Nephew PLC, F.Hoffmann-La Roche Ltd, Sanofi, Chugai Pharmaceutical Co, Lifecore Biomedical and LG Life Sciences Ltd.

4. What are the factors driving the Viscosupplementation industry?
The growing incidence of osteoarthritis, aging populations, the need for non-invasive therapies, improvements in hyaluronic acid formulations, more healthcare knowledge, and the desire for less expensive alternatives to surgery are the main factors propelling the viscosupplementation market.

5. Which Region held the largest market share in the Viscosupplementation industry?
North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Viscosupplementation Market report?
Product, Application, End User and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Viscosupplementation Market


6. Market Share
6.1 By Product
6.2 By Application
6.3 By End User
6.4 By Countries


7. Product
7.1 Single Injection
7.2 Three Injection
7.3 Five Injection


8. Application
8.1 Knee Osteoarthritis
8.2 Hip Osteoarthritis
8.3 Hand/Wrist Osteoarthritis
8.4 Ankle/Foot Osteoarthritis
8.5 Others


9. End User
9.1 Hospitals
9.2 Orthopedic clinics/Ambulatory Surgical Centers


10. Countries
10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 United Arab Emirates
10.5.3 South Africa


11. Porter’s Five Forces
11.1 Bargaining Power of Buyer
11.2 Bargaining Power of Supplier
11.3 Threat of New Entrants
11.4 Rivalry among Existing Competitors
11.5 Threat of Substitute Products


12. SWOT Analysis
12.1 Strengths
12.2 Weaknesses
12.3 Opportunities
12.4 Threats


13. Key Players Analysis
13.1 Anika Therapeutics, Inc.

13.1.1 Company overview
13.1.2 Recent Development
13.1.3 Sales Analysis

13.2 Zimmer Biomet

13.2.1 Company overview
13.2.2 Recent Development
13.2.3 Sales Analysis

13.3 Smith & Nephew PLC

13.3.1 Company overview
13.3.2 Recent Development
13.3.3 Sales Analysis

13.4 F.Hoffmann-La Roche Ltd.

13.4.1 Company overview
13.4.2 Recent Development
13.4.3 Sales Analysis

13.5 Sanofi

13.5.1 Company overview
13.5.2 Recent Development
13.5.3 Sales Analysis

13.6 Chugai Pharmaceutical Co.

13.6.1 Company overview
13.6.2 Recent Development
13.6.3 Sales Analysis

13.7 Lifecore Biomedical

13.7.1 Company overview
13.7.2 Recent Development
13.7.3 Sales Analysis

13.8 LG Life Sciences Ltd.

13.8.1 Company overview
13.8.2 Recent Development
13.8.3 Sales Analysis